Ignite Creation Date:
2024-07-17 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06501625
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-09
Brief Title:
Ivosidenib Plus Durvalumab and GemcitabineCisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Sponsor:
Institut de Recherches Internationales Servier
Organization:
Servier
Organization Data
Organization:
Servier
Class:
INDUSTRY
Study ID:
S095031-210
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Institut de Recherches Internationales Servier
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None